Protalix BioTherapeutics Inc.’s filing revealed that its PRESIDENT AND CEO Bashan Dror acquired Company’s shares for reported $90484.0 on Oct 19 ’23. In the deal valued at $1.40 per share,64,516 shares were bought. As a result of this transaction, Bashan Dror now holds 132,516 shares worth roughly $0.15 million.
H.C. Wainwright reiterated its Protalix BioTherapeutics Inc. [PLX] rating to a Buy in a research note published on June 08, 2020; the price target was $11. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who remained covering the stock and in mid April has reiterated a ‘”a Buy”‘ rating for it. Rodman & Renshaw began covering PLX with “Buy” recommendation on April 04, 2016. Jefferies revised its rating on April 23, 2015. It rated PLX as “a Buy” which previously was an “a Hold”.
Price Performance Review of PLX
On Tuesday, Protalix BioTherapeutics Inc. [AMEX:PLX] saw its stock unchanged to $1.14. Over the last five days, the stock has lost -13.64%. Protalix BioTherapeutics Inc. shares have fallen nearly -35.96% since the year began. Nevertheless, the stocks have fallen -53.85% over the past one year. While a 52-week high of $3.55 was reached on 01/03/24, a 52-week low of $1.14 was recorded on 04/16/24. SMA at 50 days reached $1.3822, while 200 days put it at $1.5940. A total of 0.29 million shares were traded, compared to the trading of 0.43 million shares in the previous session.
Levels Of Support And Resistance For PLX Stock
The 24-hour chart illustrates a support level at 1.1233, which if violated will result in even more drops to 1.1067. On the upside, there is a resistance level at 1.1633. A further resistance level may holdings at 1.1867. The Relative Strength Index (RSI) on the 14-day chart is 35.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0738, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.45%. Stochastics %K at 12.63% indicates the stock is a buying.
The most recent change occurred on November 12, 2014 when R. F. Lafferty resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $5.
